サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：GLP-1受容体作動薬市場- 薬剤クラス別（セマグルチド、デュラグルチド、リラグルチド、エキセナチド）、投与経路別（非経口）、用途別（2型糖尿病、肥満）、流通別（病院、小売）、世界予測、2023～2032年
市場調査レポート
商品コード
1292429

GLP-1受容体作動薬市場- 薬剤クラス別（セマグルチド、デュラグルチド、リラグルチド、エキセナチド）、投与経路別（非経口）、用途別（2型糖尿病、肥満）、流通別（病院、小売）、世界予測、2023～2032年

GLP-1 Receptor Agonist Market - By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Route of Administration (Parenteral), By Application (Type 2 Diabetes, Obesity), By Distribution (Hospital, Retail), Global Forecast, 2023 - 2032
出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 160 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
GLP-1受容体作動薬市場- 薬剤クラス別（セマグルチド、デュラグルチド、リラグルチド、エキセナチド）、投与経路別（非経口）、用途別（2型糖尿病、肥満）、流通別（病院、小売）、世界予測、2023～2032年
出版日: 2023年05月24日
発行: Global Market Insights Inc.
ページ情報: 英文 160 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

GLP-1受容体作動薬市場は、糖尿病の高い有病率とGLP-1受容体作動薬を使用する利点に関する患者の意識の高まりにより、2023年から2032年にかけて大きな成長を遂げると予想されています。

GLP-1受容体作動薬は、血糖値を調整するグルカゴン様ペプチド-1ホルモンの作用を模倣することで機能します。これらの薬は、グルカゴンの放出を抑制する一方で、インスリンの放出を刺激し、胃の排出を遅らせ、満腹感を促進させるのに役立ちます。

これらの薬は注射で投与され、血糖値の低下、体重減少の促進、心血管系の予後の改善に効果があることが知られています。糖尿病人口の継続的な増加に伴い、GLP-1受容体作動薬の需要は拡大し、市場の成長を牽引するものと期待されています。患者教育プログラム、アドボカシー活動、ヘルスケアキャンペーンは、これらの薬剤に対する認識と理解の向上に大きく寄与しています。さらに、製薬会社は、有効性、利便性、患者のコンプライアンスを向上させた新しい製剤を開発するために、研究開発に投資しています。これらの技術革新やパイプラインの開発は、GLP-1受容体作動薬治療の利用可能な選択肢を広げ、最終的に業界の成長をサポートすることになるでしょう。

GLP-1受容体作動薬市場は、薬物クラス、アプリケーション、地域に基づいて分類されます。

薬物クラス別では、2型糖尿病の治療にエクセナチドGLP-1受容体作動薬が広く使用されていることから、2032年までにエクセナチドセグメントが適正な評価額を獲得すると考えられます。血糖値の低下、体重減少、心血管転帰の改善など、これらの薬剤の有効性が、その採用を後押ししています。さらに、エキセナチドをベースとした新しい製剤の継続的な展開が、今後10年間のセグメント成長を刺激すると考えられます。

用途別では、2032年までに肥満症領域がGLP-1受容体作動薬市場で大きなシェアを占めると推定されます。GLP-1受容体作動薬は、食欲を抑え、満腹感を促進し、体重減少を助けることで、肥満症の管理に有望な結果を示しています。世界の肥満の蔓延が続く中、効果的な肥満管理オプションや非外科的・薬理学的アプローチによる減量に対する需要が高まっており、市場成長に寄与しています。

地域別では、欧州のGLP-1受容体作動薬市場が2032年までに大きな売上シェアを占めると予想されています。これは、同地域における糖尿病および肥満の有病率の増加、個別化医療や革新的な治療アプローチへの注目の高まりなどのいくつかの要因によります。さらに、有利な償還政策、糖尿病管理を促進する政府の取り組み、確立された市場プレイヤーの存在が、この地域全体でGLP-1受容体作動薬の採用を促進します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 GLP-1受容体作動薬の市場洞察

  • 業界情勢、2018年～2032年
  • 業界への影響要因
    • 促進要因
      • 糖尿病や肥満などの慢性疾患の有病率の増加
      • 新規治療薬開発のための研究開発活動の活発化
      • 経口GLP-1受容体作動薬の製剤化の進展
      • 糖尿病の診断と治療法に関する意識の高まり
    • 業界の潜在的リスク＆課題
      • 少数のGLP-1アゴニスト薬に関連する有害作用
      • 市場参入企業別製品リコール
  • 成長性分析
    • 薬物クラス別
    • 投与経路別
    • アプリケーション別
    • 販売チャネル別
  • COVID-19の影響分析
  • 臨床試験分析
  • 規制状況
  • ポーター分析
  • PESTEL分析

第4章 競合情勢、2022年

  • イントロダクション
  • 企業マトリックス分析、2022年
  • 世界企業の市場シェア分析、2022年
  • 競合のポジショニングマトリックス、2022年
  • 戦略的ダッシュボード、2022年

第5章 GLP-1受容体作動薬の市場推計・予測：薬剤クラス別

  • 主要動向：薬剤クラス別
  • セマグルチド
  • デュラグルチド
  • リラグルチド
  • エキセナチド
  • その他の薬剤クラス

第6章 GLP-1受容体作動薬の市場推計・予測：投与経路別

  • 主な動向：投与経路別
  • 非経口剤
  • 経口剤

第7章 GLP-1受容体作動薬市場の推定・予測：用途別

  • 主な動向：用途別
  • 2型糖尿病
  • 肥満症
  • その他の用途

第8章 GLP-1受容体作動薬の市場推計・予測：流通チャネル別

  • 主要動向：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 GLP-1受容体作動薬市場の推定・予測：地域別

  • 主要動向：地域別
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • スイス
    • その他欧州
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 中東・アフリカ地域
    • 南アフリカ
    • サウジアラビア
    • その他中東とアフリカ

第10章 企業プロファイル

  • Eli Lilly and Company
  • Sanofi
  • Novo-Nordisk A/S
  • AstraZeneca
  • Pfizer, Inc.
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
図表

Data Tables

  • TABLE 1 Product mapping
  • TABLE 2 Market revenue, by drug class (2022)
  • TABLE 3 Market revenue, by route of administration (2022)
  • TABLE 4 Market revenue, by application (2022)
  • TABLE 5 Market revenue, by distribution channel (2022)
  • TABLE 6 Market share, by region (2022)
  • TABLE 7 Global GLP-1 receptor agonist market size, by region, 2018 - 2022 (USD Million)
  • TABLE 8 Global GLP-1 receptor agonist market size, by region, 2023 - 2032 (USD Million)
  • TABLE 9 Global GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 10 Global GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 11 Global GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 12 Global GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 13 Global GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 14 Global GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 15 Global GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 16 Global GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 17 Industry impact forces
  • TABLE 18 Competitive benchmarking of major market players
  • TABLE 19 Competitive positioning matrix: Classification criteria
  • TABLE 20 Strategic outlook matrix: Classification criteria
  • TABLE 21 Semaglutide market size, by drug type, 2018 - 2022 (USD Million)
  • TABLE 22 Semaglutide market size by drug type, 2023 - 2032 (USD Million)
  • TABLE 23 Dulaglutide market size, 2018 - 2022 (USD Million)
  • TABLE 24 Dulaglutide market size, 2023 - 2032 (USD Million)
  • TABLE 25 Liraglutide market size, 2018 - 2022 (USD Million)
  • TABLE 26 Liraglutide market size, 2023 - 2032 (USD Million)
  • TABLE 27 Exenatide market size, 2018 - 2022 (USD Million)
  • TABLE 28 Exenatide market size, 2023 - 2032 (USD Million)
  • TABLE 29 Other drug classes market size, 2018 - 2022 (USD Million)
  • TABLE 30 Other drug classes market size, 2023 - 2032 (USD Million)
  • TABLE 31 Parenteral market size, 2018 - 2022 (USD Million)
  • TABLE 32 Parenteral market size, 2023 - 2032 (USD Million)
  • TABLE 33 Oral market size, 2018 - 2022 (USD Million)
  • TABLE 34 Oral market size, 2023 - 2032 (USD Million)
  • TABLE 35 Type 2 diabetes mellitus market size, 2018 - 2022 (USD Million)
  • TABLE 36 Type 2 diabetes mellitus market size, 2023 - 2032 (USD Million)
  • TABLE 37 Obesity market size, 2018 - 2022 (USD Million)
  • TABLE 38 Obesity market size, 2023 - 2032 (USD Million)
  • TABLE 39 Other applications market size, 2018 - 2022 (USD Million)
  • TABLE 40 Other applications market size, 2023 - 2032 (USD Million)
  • TABLE 41 Hospital pharmacies market size, 2018 - 2022 (USD Million)
  • TABLE 42 Hospital pharmacies market size, 2023 - 2032 (USD Million)
  • TABLE 43 Retail pharmacies market size, 2018 - 2022 (USD Million)
  • TABLE 44 Retail pharmacies market size, 2023 - 2032 (USD Million)
  • TABLE 45 Online pharmacies market size, 2018 - 2022 (USD Million)
  • TABLE 46 Online pharmacies market size, 2023 - 2032 (USD Million)
  • TABLE 47 North America GLP-1 receptor agonist market size, by country, 2018 - 2022 (USD Million)
  • TABLE 48 North America GLP-1 receptor agonist market size, by country, 2023 - 2032 (USD Million)
  • TABLE 49 North America GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 50 North America GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 51 North America GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 52 North America GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 53 North America GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 54 North America GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 55 North America GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 56 North America GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 57 U.S. GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 58 U.S. GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 59 U.S. GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 60 U.S. GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 61 U.S. GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 62 U.S. GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 63 U.S. GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 64 U.S. GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 65 Canada GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 66 Canada GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 67 Canada GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 68 Canada GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 69 Canada GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 70 Canada GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 71 Canada GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 72 Canada GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 73 Europe GLP-1 receptor agonist market size, by country, 2018 - 2022 (USD Million)
  • TABLE 74 Europe GLP-1 receptor agonist market size, by country, 2023 - 2032 (USD Million)
  • TABLE 75 Europe GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 76 Europe GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 77 Europe GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 78 Europe GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 79 Europe GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 80 Europe GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 81 Europe GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 82 Europe GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 83 Germany GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 84 Germany GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 85 Germany GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 86 Germany GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 87 Germany GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 88 Germany GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 89 Germany GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 90 Germany GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 91 UK GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 92 UK GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 93 UK GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 94 UK GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 95 UK GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 96 UK GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 97 UK GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 98 UK GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 99 France GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 100 France GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 101 France GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 102 France GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 103 France GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 104 France GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 105 France GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 106 France GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 107 Spain GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 108 Spain GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 109 Spain GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 110 Spain GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 111 Spain GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 112 Spain GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 113 Spain GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 114 Spain GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 115 Italy GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 116 Italy GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 117 Italy GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 118 Italy GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 119 Italy GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 120 Italy GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 121 Italy GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 122 Italy GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 123 Switzerland GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 124 Switzerland GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 125 Switzerland GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 126 Switzerland GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 127 Switzerland GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 128 Switzerland GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 129 Switzerland GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 130 Switzerland GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 131 Rest of Europe GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 132 Rest of Europe GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 133 Rest of Europe GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 134 Rest of Europe GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 135 Rest of Europe GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 136 Rest of Europe GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 137 Rest of Europe GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 138 Rest of Europe GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 139 Asia Pacific GLP-1 receptor agonist market size, by country, 2018 - 2022 (USD Million)
  • TABLE 140 Asia Pacific GLP-1 receptor agonist market size, by country, 2023 - 2032 (USD Million)
  • TABLE 141 Asia Pacific GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 142 Asia Pacific GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 143 Asia Pacific GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 144 Asia Pacific GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 145 Asia Pacific GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 146 Asia Pacific GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 147 Asia Pacific GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 148 Asia Pacific GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 149 China GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 150 China GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 151 China GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 152 China GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 153 China GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 154 China GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 155 China GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 156 China GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 157 Japan GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 158 Japan GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 159 Japan GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 160 Japan GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 161 Japan GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 162 Japan GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 163 Japan GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 164 Japan GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 165 India GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 166 India GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 167 India GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 168 India GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 169 India GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 170 India GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 171 India GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 172 India GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 173 Australia GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 174 Australia GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 175 Australia GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 176 Australia GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 177 Australia GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 178 Australia GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 179 Australia GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 180 Australia GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 181 South Korea GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 182 South Korea GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 183 South Korea GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 184 South Korea GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 185 South Korea GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 186 South Korea GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 187 South Korea GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 188 South Korea GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 189 Rest of Asia Pacific GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 190 Rest of Asia Pacific GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 191 Rest of Asia Pacific GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 192 Rest of Asia Pacific GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 193 Rest of Asia Pacific GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 194 Rest of Asia Pacific GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 195 Rest of Asia Pacific GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 196 Rest of Asia Pacific GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 197 Latin America GLP-1 receptor agonist market size, by country, 2018 - 2022 (USD Million)
  • TABLE 198 Latin America GLP-1 receptor agonist market size, by country, 2023 - 2032 (USD Million)
  • TABLE 199 Latin America GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 200 Latin America GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 201 Latin America GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 202 Latin America GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 203 Latin America GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 204 Latin America GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 205 Latin America GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 206 Latin America GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 207 Brazil GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 208 Brazil GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 209 Brazil GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 210 Brazil GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 211 Brazil GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 212 Brazil GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 213 Brazil GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 214 Brazil GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 215 Mexico GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 216 Mexico GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 217 Mexico GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 218 Mexico GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 219 Mexico GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 220 Mexico GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 221 Mexico GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 222 Mexico GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 223 Rest of Latin America GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 224 Rest of Latin America GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 225 Rest of Latin America GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 226 Rest of Latin America GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 227 Rest of Latin America GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 228 Rest of Latin America GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 229 Rest of Latin America GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 230 Rest of Latin America GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 231 Middle East & Africa GLP-1 receptor agonist market size, by country, 2018 - 2022 (USD Million)
  • TABLE 232 Middle East & Africa GLP-1 receptor agonist market size, by country, 2023 - 2032 (USD Million)
  • TABLE 233 Middle East & Africa GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 234 Middle East & Africa GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 235 Middle East & Africa GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 236 Middle East & Africa GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 237 Middle East & Africa GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 238 Middle East & Africa GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 239 Middle East & Africa GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 240 Middle East & Africa GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 241 South Africa GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 242 South Africa GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 243 South Africa GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 244 South Africa GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 245 South Africa GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 246 South Africa GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 247 South Africa GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 248 South Africa GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 249 Saudi Arabia GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 250 Saudi Arabia GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 251 Saudi Arabia GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 252 Saudi Arabia GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 253 Saudi Arabia GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 254 Saudi Arabia GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 255 Saudi Arabia GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 256 Saudi Arabia GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)
  • TABLE 257 Rest of Middle East & Africa GLP-1 receptor agonist market size, by drug class, 2018 - 2022 (USD Million)
  • TABLE 258 Rest of Middle East & Africa GLP-1 receptor agonist market size, by drug class, 2023 - 2032 (USD Million)
  • TABLE 259 Rest of Middle East & Africa GLP-1 receptor agonist market size, by route of administration, 2018 - 2022 (USD Million)
  • TABLE 260 Rest of Middle East & Africa GLP-1 receptor agonist market size, by route of administration, 2023 - 2032 (USD Million)
  • TABLE 261 Rest of Middle East & Africa GLP-1 receptor agonist market size, by application, 2018 - 2022 (USD Million)
  • TABLE 262 Rest of Middle East & Africa GLP-1 receptor agonist market size, by application, 2023 - 2032 (USD Million)
  • TABLE 263 Rest of Middle East & Africa GLP-1 receptor agonist market size, by distribution channel, 2018 - 2022 (USD Million)
  • TABLE 264 Rest of Middle East & Africa GLP-1 receptor agonist market size, by distribution channel, 2023 - 2032 (USD Million)

Charts & Figures

  • FIG 1 GMI report coverage: Critical research elements
  • FIG 2 Top-down approach
  • FIG 3 Market estimation and forecast methodology
  • FIG 4 Market forecasting methodology
  • FIG 5 Breakdown of primary participants
  • FIG 6 GLP-1 receptor agonist industry 36 degree synopsis, 2018 - 2032
  • FIG 7 Growth potential analysis, by drug class
  • FIG 8 Growth potential analysis, by route of administration
  • FIG 9 Growth potential analysis, by application
  • FIG 10 Growth potential analysis, by distribution channel
  • FIG 11 Porter's analysis
  • FIG 12 PESTEL analysis
  • FIG 13 Company matrix analysis, 2022
  • FIG 14 Global Company market share analysis, 2022
  • FIG 15 Competitive positioning matrix, 2022
  • FIG 16 Strategic dashboard, 2022
目次
Product Code: 5864

GLP-1 Receptor Agonist Market is poised to witness significant growth from 2023 to 2032 owing to the high prevalence of diabetes and increasing patient awareness about the benefits of using GLP-1 receptor agonists. GLP-1 receptor agonists work by mimicking the action of glucagon-like peptide-1 hormone that regulates blood sugar. These medications help stimulate the release of insulin, slow-down gastric emptying and promote a feeling of fullness while inhibiting the release of glucagon.

These drugs are administered via injections and are known for their effectiveness in reducing blood sugar levels, promoting weight loss, and improving cardiovascular outcomes. With the continuous surge in the diabetic population, the demand for GLP-1 receptor agonists is poised to grow, driving the market growth. Patient education programs, advocacy efforts, and healthcare campaigns have significantly contributed to the increased awareness and understanding of these drugs. Furthermore, pharmaceutical companies are investing in R&D to develop new formulations with improved efficacy, convenience, and patient compliance. These innovations and pipeline developments will expand the available options for GLP-1 receptor agonist therapies, eventually supporting industry growth.

The GLP-1 receptor agonist market is categorized based on drug class, application, and region.

As per drug class, the exenatide segment will amass a decent valuation by 2032, owing to the widespread application of exenatide GLP-1 receptor agonists in treating type 2 diabetes. The effectiveness of these drugs in reducing blood sugar levels, promoting weight loss, and improving cardiovascular outcomes has favored their adoption. Additionally, the continuous rollouts of new exenatide-based formulations will stimulate segment growth over the next ten years.

Based on application, the obesity segment is estimated to hold a sizable share of the GLP-1 receptor agonists market by 2032. GLP-1 receptor agonists have shown promising results in managing obesity by reducing appetite, promoting satiety, and aiding in weight loss. As the global obesity epidemic continues to rise, there is an increasing demand for effective obesity management options and non-surgical and pharmacological approaches to weight loss, thereby contributing to market growth.

Regionally, the Europe GLP-1 receptor agonists market is set to account for a substantial revenue share by 2032 due to several factors including the increasing prevalence of diabetes and obesity in the region, along with a growing focus on personalized medicine and innovative treatment approaches. Additionally, favorable reimbursement policies, government initiatives promoting diabetes management, and the presence of established market players will drive the adoption of GLP-1 receptor agonists across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast calculation
  • 1.4 Covid-19 impact analysis at global level
  • 1.5 Data Validation
  • 1.6 Data Sources
    • 1.6.1 Secondary
      • 1.6.1.1 Paid sources
      • 1.6.1.2 Public sources
    • 1.6.2 Primary

Chapter 2 Executive Summary

  • 2.1 GLP-1 receptor agonist industry 360 degree synopsis, 2018 - 2032 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Region trends
    • 2.1.3 Drug class trends
    • 2.1.4 Route of administration
    • 2.1.5 Application trends
    • 2.1.6 Distribution channel trends

Chapter 3 GLP-1 Receptor Agonist Market Insights

  • 3.1 Industry landscape, 2018 - 2032 (USD Million)
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
      • 3.2.1.2 Increasing R&D activities for developing novel therapeutics
      • 3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
      • 3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
      • 3.2.2.2 Product recalls by market players
  • 3.3 Growth potential analysis
    • 3.3.1 By drug class
    • 3.3.2 By route of administration
    • 3.3.3 By application
    • 3.3.4 By distribution channel
  • 3.4 COVID-19 impact analysis
  • 3.5 Clinical trial analysis
  • 3.6 Regulatory landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Global company market share analysis, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 GLP-1 Receptor Agonist Market Estimates and Forecast, By Drug Class (USD Million)

  • 5.1 Key trends, by drug class
  • 5.2 Semaglutide
  • 5.3 Dulaglutide
  • 5.4 Liraglutide
  • 5.5 Exenatide
  • 5.6 Other drug classes

Chapter 6 GLP-1 Receptor Agonist Market Estimates and Forecast, By Route of Administration (USD Million)

  • 6.1 Key trends, by route of administration
  • 6.2 Parenteral
  • 6.3 Oral

Chapter 7 GLP-1 Receptor Agonist Market Estimates and Forecast, By Application (USD Million)

  • 7.1 Key trends, by application
  • 7.2 Type 2 diabetes mellitus
  • 7.3 Obesity
  • 7.4 Other applications

Chapter 8 GLP-1 Receptor Agonist Market Estimates and Forecast, By Distribution Channel (USD Million)

  • 8.1 Key trends, by distribution channel
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 GLP-1 Receptor Agonist Market Estimates and Forecast, By Region (USD Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Switzerland
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Eli Lilly and Company
  • 10.2 Sanofi
  • 10.3 Novo-Nordisk A/S
  • 10.4 AstraZeneca
  • 10.5 Pfizer, Inc.
  • 10.6 Amgen, Inc.
  • 10.7 Innovent Biologics, Inc.
  • 10.8 PegBio Co., Ltd.
  • 10.9 Sun Pharmaceutical Industries Ltd.
  • 10.10 Boehringer Ingelheim International GmbH